Slides and webcasts from ESMO Virtual Plenaries are open to all ESMO Account holders, according to the presenters' agreement to release them.
Login and Watch now!
ESMO Virtual Plenary: May 2022
- Start date
- 19 May 2022
- End date
- 20 May 2022
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Thursday, 19 May 2022 |
Friday, 20 May 2022 |
|---|---|
18:30-19:30 CEST |
13:00-14:10 CEST / 20:00-21:10 SGT |
Programme
Welcome and introduction, Scientific background and context Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) Phillipe Moreau, University Hospital Hôtel-Dieu, Nantes, France Critical analysis and perspectives Live Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: Webcast of 19 May IKEMA presentations, Discussion and Q&A (ii) Chair: Pankaj Malhotra, Postgraduate Institute of Medical Education & Research (PGIMER) Chandigarh, India Phillipe Moreau, University Hospital Hôtel-Dieu, Nantes, France Francesca Gay, University of Turin, Turin, Italy Simon Harrison, Peter MacCallum Cancer Centre, Melbourne, Australia Efstathios Kastritis, National and Kapodistrian University of Athens, Athens, Greece |
